| Literature DB >> 32605995 |
Tomoyuki Uchihara1,2, Keisuke Miyake1,2, Atsuko Yonemura1,2, Yoshihiro Komohara3, Rumi Itoyama1,2, Mayu Koiwa1,2, Tadahito Yasuda1,2, Kota Arima1,2, Kazuto Harada1,4, Kojiro Eto1, Hiromitsu Hayashi1, Masaaki Iwatsuki1, Shiro Iwagami1, Yoshifumi Baba1, Naoya Yoshida1, Masakazu Yashiro5,6, Mari Masuda7, Jaffer A Ajani4, Patrick Tan8, Hideo Baba9,10, Takatsugu Ishimoto9,2.
Abstract
Extracellular vesicles (EV) from cancer-associated fibroblasts (CAF) are composed of diverse payloads. Although CAFs impact the aggressive characteristics of gastric cancer cells, the contribution of CAF-EV to gastric cancer progression has not been elucidated. Here, we investigated the molecular mechanism of the changes in gastric cancer characteristics induced by CAF-EV. CAF abundance in gastric cancer tissues was associated with poor prognosis of patients with gastric cancer receiving chemotherapy. Moreover, CAF-EV induced tubular network formation and drug resistance of gastric cancer cells in the extracellular matrix (ECM). Comprehensive proteomic analysis of CAF-EV identified that Annexin A6 plays a pivotal role in network formation and drug resistance of gastric cancer cells in the ECM via activation of β1 integrin-focal adhesion kinase (FAK)-YAP. A peritoneal metastasis mouse model revealed that CAF-EV induced drug resistance in peritoneal tumors, and inhibition of FAK or YAP efficiently attenuated gastric cancer drug resistance in vitro and in vivo. These findings demonstrate that drug resistance is conferred by Annexin A6 in CAF-EV and provide a potential avenue for overcoming gastric cancer drug resistance through the inhibition of FAK-YAP signaling in combination with conventional chemotherapeutics. SIGNIFICANCE: This study elucidates a novel molecular mechanism through which Annexin A6 in CAF-EV activates FAK-YAP by stabilizing β1 integrin at the cell surface of gastric cancer cells and subsequently induces drug resistance. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/16/3222/F1.large.jpg. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32605995 DOI: 10.1158/0008-5472.CAN-19-3803
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701